· Prostate Cancer
· Colon Cancer
· Breast Cancer
· Leukemia
» Autoantibodies
· Proteomics
· Molecular Imaging
· Promoters
· Gene Functional Classification
One of the major goals in the fight against cancer is the ability to detect the primary tumor before tumor cells that can potentially metastasize are released into the bloodstream. There has been limited success in research areas of tumor markers, indicative DNA and whole tumor cells in peripheral blood indicating the presence of a potentially malignant growth. Low experimental specificity and sensitivity have limited many of these projects.
Our collaborator at the University of Nottingham, Dr. John Robertson, has developed a test for the detection of autoantibodies to known tumor markers. He has shown that these assays are extremely successful at detecting early stage epithelial cell derived carcinomas with only a small amount of optimization of the antigen presentation technology. He has also found ways to isolate these naturally derived autoantibodies, such that they might be used to detect the "modified" tumor marker proteins. His early data indicates that some combination of auto-antibody/modified antigen detection technology can create a powerful and unduplicated tool for early cancer screening.
Under our exclusive license agreement with the University of Nottingham, BIOwulf owns the exclusive rights to the output of Dr. Robertsonšs research: development of a panel of immunoassays for the assay of autoantibodies in human serum.